The Latest Breaking News from Eli Lilly

AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion

“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine, tells Fortune.

Fortune · Jun 22

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

MarketBeat · Jun 18

Trump's unusual stock frenzy: Portfolio shows 3,600 trades in 90 days

Trump's investment accounts saw thousands of trades totaling hundreds of millions of dollars between January and March. This feverish activity, dominated by tech stocks, has drawn scrutiny from lawmakers and ethics experts over potential conflicts of interest, though the Trump Organization denies the president's direct involvement.

The Economic Times · Jun 16

FDA issues new kidney warning for weight loss pill

Alli was the first over-the-counter weight loss pill approved by the U.S. Food and Drug Administration

The Independent UK · Jun 11

Medicare Is About to Cover Weight-Loss Drugs for the First Time — Here's What the GLP-1 Bridge Program Means for Millions of Americans with Obesity

Medicare's GLP-1 Bridge launches July 1, 2026, offering eligible Part D enrollees Wegovy and Zepbound for $50/month — the first-ever Medicare coverage for obesity-specific GLP-1 drugs.

Medical Daily · Jun 10

Innovation in medicine is having a breakthrough moment

Recent weeks have featured a series of positive developments.

Axios · Jun 7

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity. Patients also experienced substantial weight loss. These findings were shared at an American Diabetes Association conference. Retatrutide targets multiple hormones related to obesity and…

The Economic Times · Jun 7

Phemex Expands TradFi Offering Beyond 70 Assets, Bringing Global Equities to 24/7 Crypto Markets

APIA, Samoa, June 3, 2026 /PRNewswire/ -- Phemex, a user-first crypto exchange, expands its TradFi ecosystem to 73 active assets. It includes the recent addition of several high-performance contracts, ranging from healthcare leaders Eli Lilly (LLY) and Novo Nordisk (NVO) to global semiconductor and technology powerhouses like Samsung (SAMSUNG) and…

AAP · Jun 3

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

MarketBeat · Jun 2

US stocks today: S&P 500 and Nasdaq hit record closing highs as US and Iran agree to extend ceasefire

The S&P 500 and Nasdaq hit record closing highs as hopes of a US Iran ceasefire extension boosted sentiment. Investors also digested US inflation rising to a three-year high and weaker GDP revision. AI and tech stocks led gains, with Microsoft, Snowflake, Eli Lilly and Marvell among top movers today.

The Economic Times · May 28